The 2020 AHA/ACC guideline provides updated recommendations for the diagnosis, genetic screening, risk stratification, and treatment of hypertrophic cardiomyopathy in adult and pediatric patients.
The 2020 AHA/ACC guideline provides updated, evidence-based recommendations for the comprehensive management of hypertrophic cardiomyopathy.
AIM: This executive summary of the hypertrophic cardiomyopathy clinical practice guideline provides recommendations and algorithms for clinicians to diagnose and manage hypertrophic cardiomyopathy in adult and pediatric patients as well as supporting documentation to encourage their use. METHODS: A comprehensive literature search was conducted from January 1, 2010, to April 30, 2020, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Collaboration, Agency for Healthcare Research and Quality reports, and other relevant databases. STRUCTURE: Many recommendations from the earlier hypertrophic cardiomyopathy guidelines have been updated with new evidence or a better understanding of earlier evidence. This summary operationalizes the recommendations from the full guideline and presents a combination of diagnostic work-up, genetic and family screening, risk stratification approaches, lifestyle modifications, surgical and catheter interventions, and medications that constitute components of guideline directed medical therapy. For both guideline-directed medical therapy and other recommended drug treatment regimens, the reader is advised to follow dosing, contraindications and drug-drug interactions based on product insert materials.
“The application of contemporary cardiovascular treatments and management strategies to hypertrophic cardiomyopathy over the last decade have altered the natural history and course of this genetic heart disease, now providing the vast majority of at-risk HCM patients the reasonable expectation for extended (if not normal) longevity and excellent quality of life.”
Ommen et al. (Fri,) conducted a review in Hypertrophic cardiomyopathy. Guideline-directed medical therapy and interventions was evaluated. The 2020 AHA/ACC guideline provides updated recommendations for the diagnosis, genetic screening, risk stratification, and treatment of hypertrophic cardiomyopathy in adult and pediatric patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: